425. Chikungunya in Solid Organ Transplant Recipients, a case series and literature review
Session: Poster Abstract Session: Global Health and Travel Medicine
Thursday, October 4, 2018
Room: S Poster Hall
Background: Chikungunya virus is a recent emerging arbovirus in Latin America. Clinical manifestations can vary from fever and rash to severe chronic inflammatory arthritis. Few reports have been published regarding this infection in immunocompromised patients, including in solid organ transplant (SOT) recipients.
Methods: We presented a case series of SOT recipients with confirmed Chikungunya infection by positive RT-PCR (LightMix® kit Chikungunya-virus, Light Cycler® Roche Diagnostics), during the 2015 epidemic in Colombia. In addition, we conducted a literature review, searching PUBMED, EMBASE, LILACS regarding Chikungunya infection in SOT recipients.
Results: Ten SOT recipients were included (five kidneys, four liver, and one liver/kidney transplant). The mean age of the transplant recipients was 47 years, 70% were women. The most frequent symptoms were arthralgia and fever. None of the patients required treatment in the intensive care unit; no fatal cases or graft rejection were reported. None of our patients had recurrent arthritis during the three months follow up. In the literature review, we found 21 cases reported. All of them had a benign clinical course with no severe complications or death. No chronic inflammatory arthritis cases were reported.
Conclusion: CHIK infection in SOT recipient have a benign course, and have no chronic recurrent arthritis. We proposed that immunosuppression could decrease the risk of severe or chronic inflammatory manifestations.
Fernando Rosso, MD1, Sarita Rodríguez, MD2, Jorge Cedano, MD1 and Barbara Lucia Mora, MD1, (1)Infectious Diseases, Fundación Valle del Lili, Cali, Colombia, (2)Clinical Research Center, Fundacion Valle del Lili, Cali, Colombia


F. Rosso, None

S. Rodríguez, None

J. Cedano, None

B. L. Mora, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.